Learn languages naturally with fresh, real content!

Popular Topics
Explore By Region
U.S. cancer centers slowly adopt subcutaneous immunotherapy due to billing risks, despite patient and staff benefits.
Cancer centers are cautiously adopting subcutaneous immune checkpoint inhibitors, prioritizing stable reimbursement through permanent J-codes over rapid rollout despite patient and staff benefits.
While these formulations improve convenience, reduce infusion times, and lower costs by eliminating IV supplies, institutions delay full implementation due to billing uncertainties and financial risks tied to high-cost drugs like pembrolizumab.
Flexible prescribing models allow select patient switches, and some systems streamline adoption via electronic medical record updates.
Future challenges include the Inflation Reduction Act’s 2028 pricing rules and biosimilar IV drugs, which may complicate long-term strategy.
Despite nursing concerns over manual injection demands, growing use is supported by patient satisfaction and operational gains.
Los centros de cáncer de Estados Unidos adoptan lentamente la inmunoterapia subcutánea debido a los riesgos de facturación, a pesar de los beneficios para pacientes y personal.